Leukemia - search results

Two genetic mutations could explain the higher incidence and worse prognosis of B-cell acute lymphoblastic leukemia in children from Hispanic or Latino backgrounds. The team behind the study hopes a therapeutic strategy targeting these variants could help improve prognosis for children in this group.

Research explains how mutations in the RUNX1 gene, which encodes a protein that guides the way hematopoietic stem cells change into adult blood cells, can influence blood cell development and cause different types of cancer and other blood disorders.

Swedish research shows that a whole-blood assay can predict if leukemia patients will experience cytokine release syndrome, an excessive immune reaction seen in some patients given rituximab and similar therapies.

Researchers from the Cleveland Clinic have discovered a new class of drugs that, if approved, could be effective for treating myeloid leukemia with TET2 gene mutations.

The researchers have now shown the protective microenvironment in human bone marrow also gives leukemia cells with insufficient expression of BRCA1 and BRCA2 genes the ability to resist anticancer drugs known as PARP inhibitors, hinging on overexpression of transforming growth factor beta receptor (TGFßR) kinase.

St. Jude researchers showed that an inherited variant of the GATA3 gene is tied to minimal residual disease levels and response to therapy for acute lymphoblastic leukemia.

The researchers from the German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn analyzed the gene activity of cells found in the blood, which could eventually support conventional diagnostics and accelerate the beginning of therapy.

Investigators at St. Jude Children’s Research Hospital used the test to identify bacteria that cause blood infections in 12 samples out of 16 tested—a 75% success rate.

Statistics can be a great tool for analyzing datasets and it can also be a sobering means to provide a stark reality. For instance,...

This large cell-line derived myeloid cancer reference standard enables faster, more reliable, and more cost-effective assay validation.